DDO-2093

立即咨询

DDO-2093

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2250024-74-7

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品介绍

DDO-2093 是一种有效的MLL1和WDR5蛋白-蛋白相互作用抑制剂 (IC₅₀=8.6 nM;K_d=11.6 nM)，具有抗肿瘤活性。DDO-2093 选择性抑制 MLL 复合物的催化活性。

生物活性

DDO-2093 is a potentMLL1-WDR5 protein-protein interactioninhibitor (IC₅₀=8.6 nM;K_d=11.6 nM) with antitumor activity. DDO-2093 selectively inhibits the catalytic activity of MLL complex^[1].

体外研究
(In Vitro)

DDO-2093 (5 μM; pretreated 7 days) inhibits MLL-fusion protein dependent genes expression (HOXA9andMeis1)^[1].

Western Blot Analysis^[1]

Cell Line:	MV4-11 cells
Concentration:	1, 2.5, 5, and 10 μM
Incubation Time:	7 days
Result:	Dose-dependently reduced the mono-, di-, and trimethylation of H3K4.

体内研究
(In Vivo)

DDO-2093 (20-80 mg/kg; i.p.; every other day for 21 days) significantly suppresses the tumor size and weight in a dose-dependent manner^[1].

Animal Model:	Female nude mice (MV4-11 human leukemia cancer xenografts)^[1]
Dosage:	20 mg/kg, 40 mg/kg and 80 mg/kg
Administration:	Intraperitoneal injection; every other day for 21 days
Result:	Had the tumor volume growth inhibition (GI) values were calculated to be 13.7%, 37.6% and 63.9% with doses of 20 mg/kg, 40 mg/kg and 80 mg/kg, respectively.

分子量

614.11

Formula

C₂₉H₃₇ClFN₉O₃

CAS 号

2250024-74-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.